These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 21658570)

  • 1. Nonrandomized data on drug-eluting stents compared with coronary bypass surgery caution with interpretation.
    Head SJ; Bogers AJ; Kappetein AP
    J Am Coll Cardiol; 2011 Jun; 57(24):2457-8; author reply 2458-9. PubMed ID: 21658570
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of percutaneous coronary intervention with drug eluting stents versus coronary artery bypass grafting in patients with multivessel coronary artery disease: Meta-analysis of six randomized controlled trials.
    Fanari Z; Weiss SA; Zhang W; Sonnad SS; Weintraub WS
    Cardiovasc Revasc Med; 2015 Mar; 16(2):70-7. PubMed ID: 25662779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IIb or not IIb? Toward a rational application of left main stenting.
    Uretsky BF
    J Am Coll Cardiol; 2010 Jun; 55(23):2553-5. PubMed ID: 20513594
    [No Abstract]   [Full Text] [Related]  

  • 4. The AUTAX (Austrian Multivessel TAXUS-Stent) registry: another useful registry on stented angioplasty for multivessel disease?
    Wijns W
    JACC Cardiovasc Interv; 2009 Aug; 2(8):728-30. PubMed ID: 19695540
    [No Abstract]   [Full Text] [Related]  

  • 5. Risk stratification in 3-vessel coronary artery disease: Applying the SYNTAX Score II in the Heart Team Discussion of the SYNTAX II trial.
    Campos CM; Stanetic BM; Farooq V; Walsh S; Ishibashi Y; Onuma Y; Garcia-Garcia HM; Escaned J; Banning A; Serruys PW;
    Catheter Cardiovasc Interv; 2015 Nov; 86(6):E229-38. PubMed ID: 25946686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in bifurcation lesions treated with a single-stenting technique: six-month angiographic and 12-month clinical results of the drug-eluting balloon in bifurcations trial.
    Stella PR; Belkacemi A; Dubois C; Nathoe H; Dens J; Naber C; Adriaenssens T; van Belle E; Doevendans P; Agostoni P
    Catheter Cardiovasc Interv; 2012 Dec; 80(7):1138-46. PubMed ID: 22422607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pitfalls assessing the role of drug-eluting stents in multivessel coronary disease.
    Desai ND
    Ann Thorac Surg; 2008 Jan; 85(1):25-7. PubMed ID: 18154771
    [No Abstract]   [Full Text] [Related]  

  • 8. Percutaneous coronary intervention for small vessel coronary artery disease.
    Biondi-Zoccai G; Moretti C; Abbate A; Sheiban I
    Cardiovasc Revasc Med; 2010; 11(3):189-98. PubMed ID: 20599174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical versus percutaneous revascularization in patients with multivessel coronary artery disease.
    Davierwala PM; Mohr FW
    Curr Atheroscler Rep; 2014 Dec; 16(12):461. PubMed ID: 25344743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Class I indications for coronary artery bypass graft surgery: what is the appropriate therapy for patients with multivessel coronary disease?
    Dean LS
    JACC Cardiovasc Interv; 2009 Jul; 2(7):622-3. PubMed ID: 19628184
    [No Abstract]   [Full Text] [Related]  

  • 11. 2-year results of the AUTAX (Austrian Multivessel TAXUS-Stent) registry beyond the SYNTAX (synergy between percutaneous coronary intervention with TAXUS and cardiac surgery) study.
    Gyöngyösi M; Christ G; Lang I; Kreiner G; Sochor H; Probst P; Neunteufl T; Badr-Eslam R; Winkler S; Nyolczas N; Posa A; Leisch F; Karnik R; Siostrzonek P; Harb S; Heigert M; Zenker G; Benzer W; Bonner G; Kaider A; Glogar D;
    JACC Cardiovasc Interv; 2009 Aug; 2(8):718-27. PubMed ID: 19695539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ABSORB bioresorbable vascular scaffold: A novel, fully resorbable drug-eluting stent: Current concepts and overview of clinical evidence.
    Rizik DG; Hermiller JB; Kereiakes DJ
    Catheter Cardiovasc Interv; 2015 Oct; 86(4):664-77. PubMed ID: 26386235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1-year outcome of TRIAS HR (TRI-stent adjudication study-high risk of restenosis) a multicenter, randomized trial comparing genous endothelial progenitor cell capturing stents with drug-eluting stents.
    Klomp M; Beijk MA; Varma C; Koolen JJ; Teiger E; Richardt G; Bea F; van Geloven N; Verouden NJ; Chan YK; Woudstra P; Damman P; Tijssen JG; de Winter RJ
    JACC Cardiovasc Interv; 2011 Aug; 4(8):896-904. PubMed ID: 21851905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent).
    Alfonso F; Pérez-Vizcayno MJ; Cárdenas A; García Del Blanco B; Seidelberger B; Iñiguez A; Gómez-Recio M; Masotti M; Velázquez MT; Sanchís J; García-Touchard A; Zueco J; Bethencourt A; Melgares R; Cequier A; Dominguez A; Mainar V; López-Mínguez JR; Moreu J; Martí V; Moreno R; Jiménez-Quevedo P; Gonzalo N; Fernández C; Macaya C;
    J Am Coll Cardiol; 2014 Apr; 63(14):1378-86. PubMed ID: 24412457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of five-year outcome of sirolimus-eluting stent implantation for chronic total occlusions versus for non-chronic total occlusion (from the j-Cypher registry).
    Kato M; Kimura T; Morimoto T; Nishikawa H; Uchida F; Suzuki H; Hayashi Y; Kadota K; Mitsudo K;
    Am J Cardiol; 2012 Nov; 110(9):1282-9. PubMed ID: 22835413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unprotected left main coronary artery stenting with zotarolimus (Endeavor) drug-eluting stents: a single center retrospective experience.
    Simard T; Hibbert B; Chong AY; Ruchin P; Le May M; Labinaz M; Froeschl M; So D; Glover C; Marquis JF; O'Brien E
    Catheter Cardiovasc Interv; 2012 Aug; 80(2):E15-22. PubMed ID: 21805580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. My stent is better than your stent...Or is it?
    Bates ER; Menees DS
    JACC Cardiovasc Interv; 2011 May; 4(5):551-3. PubMed ID: 21596328
    [No Abstract]   [Full Text] [Related]  

  • 18. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
    Kandzari DE; Mauri L; Popma JJ; Turco MA; Gurbel PA; Fitzgerald PJ; Leon MB
    JACC Cardiovasc Interv; 2011 May; 4(5):543-50. PubMed ID: 21596327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Percutaneous coronary intervention of unprotected left main coronary artery disease: procedural strategies and technical considerations.
    Lee MS; Stone GW; Park SJ; Teirstein P; Moses J; Colombo A; Kandzari DE
    Catheter Cardiovasc Interv; 2012 Apr; 79(5):812-22. PubMed ID: 21793172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toward better stratification of patients with left main disease: value of clinical and angiographic-derived risk scores.
    Applegate RJ
    JACC Cardiovasc Interv; 2011 Mar; 4(3):298-9. PubMed ID: 21435607
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.